How often were lurbinectedin doses reduced due to side effects?

How often did doctors cut lurbinectedin doses because of side effects?

Most reductions happened after patients developed low blood counts. In the main lung-cancer study, 44 % of patients needed at least one dose reduction, and the main triggers were low neutrophils (25 %) or low platelets (8 %).

Do reductions affect how long patients stay on treatment?

Lowering the dose let most patients continue therapy. Median treatment duration stayed close to four months, the same length seen in patients who never needed a cut.

What side effects led to the biggest drops?

Neutropenia triggered the largest share of reductions; about one in four patients had their dose lowered after neutrophils fell below 500 cells/µL. Thrombocytopenia and fatigue each prompted reductions in fewer than one in ten patients.

How does the reduction rate compare with topotecan?

In the same trial, topotecan produced dose reductions in 52 % of patients—slightly higher than lurbinectedin’s 44 %. Both drugs were adjusted mainly for low blood counts.

When does the first reduction usually occur?

The first cut most often happened during cycle 2 or 3, after blood-count nadirs were recorded on day 15 of the previous cycle.

Can patients restart at the full dose later?

Restarting at 3.2 mg/m² after a reduction was uncommon; once lowered, most patients stayed at 2.6 mg/m² or 2.0 mg/m² for the remainder of therapy.

Are biosimilars or dose-adjusted schedules being tested?

No approved biosimilar exists, but ongoing trials are exploring every-three-week dosing at 2.6 mg/m² from day 1 to see whether fewer reductions are needed.